Search

DE-102024003705-A1 - Transdermal patch for controlled delivery of active ingredients using an electronic control system in the form of a smartwatch

DE102024003705A1DE 102024003705 A1DE102024003705 A1DE 102024003705A1DE-102024003705-A1

Abstract

The invention relates to a transdermal patch combined with an electronic control system in the form of a smartwatch. The patch features a display that shows information about the current status and drug delivery. Simultaneously, electrical contacts within the patch enable the targeted delivery of active ingredients under the skin. The system reacts in real time to the patient's condition and can be used for various applications including insulin control, blood measurement and vacuum blood tests. The invention offers precise and needs-based control of drug delivery and enables continuous monitoring and adjustment based on the patient's current needs.

Inventors

  • Fritz Schmitt

Assignees

  • ALIENWORKS S.A.

Dates

Publication Date
20260513
Application Date
20241112

Claims (15)

  1. A transdermal patch for the controlled delivery of active substances, in particular insulin, characterized in that it includes an electronic control system in the form of a smartwatch, for example an Apple Watch, which is placed on the transdermal patch and takes over the complete control of the active substance delivery.
  2. Transdermal patch after Claim 1 , characterized in that the adhesive surface of the patch contains partially metallic contacts that ensure a secure connection between the smartwatch and the patch.
  3. Transdermal patch after Claim 1 or 2 , characterized in that the patch contains an integrated battery and can be charged inductively, which ensures a continuous power supply.
  4. Transdermal patch according to one of the preceding claims, characterized in that the patch has its own display which shows information about the current status and the drug delivery.
  5. Transdermal patch according to one of the preceding claims, characterized in that electrical contacts in the patch promote the release of the active ingredient under the skin by means of an electric current, which enables precise control of the dosage.
  6. Transdermal patch according to one of the preceding claims, characterized in that the patch can send and receive data to enable bidirectional communication with the smartwatch.
  7. A transdermal patch according to one of the preceding claims, characterized in that the system responds to the patient's condition by continuously monitoring data such as blood glucose levels and other relevant parameters and adjusting the drug delivery accordingly.
  8. Transdermal patch according to one of the preceding claims, characterized in that the patch is glued to the skin and the smartwatch is placed on the back of the patch to improve the contact area and ensure an optimal connection.
  9. Transdermal patch according to one of the preceding claims, characterized in that different patch stickers are available for different applications, including insulin monitoring, blood measurement and vacuum blood tests.
  10. Transdermal patch according to one of the preceding claims, characterized in that the patch can be used for the delivery of insulin as well as for the administration of long-term medications and emergency medications such as noradrenaline for cardiac support.
  11. A transdermal patch according to one of the preceding claims, characterized in that a vibration effect accelerates the release of the active ingredient by promoting blood circulation and diffusion of the active ingredient into the skin.
  12. A transdermal patch according to one of the preceding claims, characterized in that the patch first creates a vacuum to draw blood to the surface before the active ingredient is released in order to improve the efficiency of drug absorption.
  13. Transdermal patch according to one of the preceding claims, characterized in that the electronic control system continuously adjusts the drug delivery based on the monitored patient data.
  14. A transdermal patch according to one of the preceding claims, characterized in that the patch controls the release of the active ingredient depending on external signals such as movement or rest of the patient.
  15. Transdermal patch according to one of the preceding claims, characterized in that the smartwatch provides an interface for transmitting the collected data to medical professionals in order to ensure optimal treatment and monitoring of the patient.

Description

Background of the invention The present invention relates to a transdermal patch for the controlled delivery of active substances, particularly medical drugs such as insulin. It is characterized by the integration of an electronic control system, which is attached to the transdermal patch in the form of a smartwatch, such as the Apple Watch. This combination enables precise control and adjustment of the drug delivery based on the patient's current needs and condition. Description of the invention The invention comprises a transdermal patch combined with an electronic control unit in the form of a smartwatch. The adhesive surface of the patch contains partially metallic contacts that ensure a secure connection to the smartwatch. The patch's integrated battery can be inductively charged, thus ensuring a continuous power supply. The patch features a display that shows information about the current status and drug delivery. Electrical contacts within the patch enable the delivery of active ingredients under the skin via an electric current, allowing for precise dosage control. Bidirectional communication between the patch and smartwatch allows data to be sent and received, enabling the system to react to the patient's condition in real time. The patch is applied to the skin, and the smartwatch is placed on the back of the patch, which improves the contact area and ensures an optimal connection. Various adhesive patches are available for different applications, including insulin monitoring, blood pressure measurement, and vacuum blood tests. The patch is capable of delivering insulin and other maintenance medications, as well as emergency medications such as norepinephrine. A vibration effect can accelerate drug release by promoting blood flow and diffusion of the active ingredient into the skin. Additionally, the patch initially creates a vacuum to draw blood to the surface before the drug is released, which improves the efficiency of drug absorption. This comprehensive solution offers precise and needs-based control of drug delivery and enables continuous monitoring and adjustment based on the patient's current needs. State of the art Transdermal patches are known for their ability to deliver active ingredients in a controlled manner through the skin. However, existing systems are often limited to passive drug delivery methods and do not offer the possibility of dynamically adjusting the dosage in real time. Furthermore, an efficient method for continuously monitoring patients is lacking. The construction of iontophoretic systems fundamentally requires a cathode and an anode to generate a direct current flow through the body. The electrodes are connected via aqueous buffer solutions, sometimes immobilized in gels, which ensures the flow of the active ingredient ions through the skin. However, to prevent short circuits between the electrodes, they must be applied to the skin at a sufficient distance from each other, which is why iontophoretic systems tend to be quite large. Iontophoretic transdermal therapeutic systems have already been described in numerous publications, for example on US 5,622,530 , WO 95/06497 , US 6,757,560 , US 3,991,755 , US 4,141,359 , DE 37 03 321 , WO 87/04936 , WO 91/16077 , WO 92/04938 , EP 0 532 451 , US 5,415,629 and WO00/53256 can be referred. In electrophoretic transdermal systems, ionic drugs can be delivered through the skin using two electrodes and a power source, without exposing the body to a direct current. In these systems, the electrodes are arranged opposite each other, similar to a capacitor, with the drug reservoir located between the electrodes and only one electrode facing the skin. In the patent specification US 5,533,995 Such an electrophoretic transdermal application system has been described. It comprises a reservoir containing the active ingredient and an electrode system that can be operated to deliver the active ingredient from the reservoir to the skin in a controlled manner. A self-adhesive transdermal application system with an electrode grid is from the patent. writing EP 1 457 233 The system comprises an electronic control of the electrode voltage, a carrier film (cover film) impermeable to the active ingredient, a membrane permeable to the active ingredient, a drug-containing reservoir located between the carrier film and the membrane, and a release liner. The electrode attached to the carrier film serves as the counter electrode for the electrode attached to the membrane. The system also includes a pressure-sensitive adhesive for attaching the transdermal patch to the skin surface. Solution and conclusion The present invention offers a solution to the aforementioned problems by combining a transdermal patch with an electronic control system in the form of a smartwatch. The system comprises several innovative features that enable precise and demand-based, and above all, active drug delivery. Reference symbol list Transdermal Smart Patch Sheet (1) Referen